Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (TSE:DTC)
:DTC
DTC Stock Chart & Stats
C$0.77
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.77
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.49 - C$1.66
Previous CloseN/A
Volume0.00
Average Volume (3M)80.09K
Market Cap
$46.52M
Enterprise ValueC$50.99M
Total Cash (Recent Filing)$2.08M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Nov 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,725,370
10 Day Avg. Volume87,217
30 Day Avg. Volume80,088
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-9.09
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-606.59
Enterprise Value/Ebitda-16.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.49 and its highest was C$1.66 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $46.52M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is Nov 21, 2025 which is in 19 days.
How were Defence Therapeutics’s earnings last quarter?
Currently, no data Available
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 54,725,370 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Oncolytics Biotech
―
Oncolytics Biotech
―
Helix BioPharma
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Options Prices
Currently, No data available
---